Early Haemadsorption in Major Burns
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04195126 |
Recruitment Status :
Not yet recruiting
First Posted : December 11, 2019
Last Update Posted : December 11, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Burns Multiple Organ Failure Shock Organ Dysfunction Syndrome, Multiple Renal Dysfunction Cytokine Storm | Device: CytoSorb haemadsorption device | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients included in our study are randomised into treatment or control groups. |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Outcome assessors are unaware of the patient groups. Treated patients are not informed regarding randomisation results. |
Primary Purpose: | Treatment |
Official Title: | Early Haemadsorption Treatment of Major Burn Trauma Patients |
Estimated Study Start Date : | January 1, 2020 |
Estimated Primary Completion Date : | January 1, 2023 |
Estimated Study Completion Date : | July 1, 2023 |
Arm | Intervention/treatment |
---|---|
No Intervention: Control group
Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
|
|
Active Comparator: Treatment group
Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
|
Device: CytoSorb haemadsorption device
CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device. |
- 7 days mortality [ Time Frame: Survival rate is assessed in the 7th admission day. ]The investigators assess the intensive care and post-intensive care mortality of our patients.
- 28 days mortality [ Time Frame: Survival rate is assessed in the 28th admission day. ]The investigators assess the intensive care and post-intensive care mortality of our patients.
- Levels of inflammatory and anti-inflammatory cytokines during treatment [ Time Frame: Samples are gathered on inclusion and 8, 16, 24, 48, 72, 96, 120, 148, 168 hours following. Measured data points are selected by screening. All measurements are carried out in one lot. Data will be presented in arbitrary units. ]The investigators assess the course of pro- and anti-inflammatory cytokines during ICU stay for both patient groups. Cytokines are screened by the Human Cytokine Array. Selected markers are measured individually.
- Markers of oxidative stress (ROS production, MDA levels, tyrosine isomers) [ Time Frame: Samples are gathered on inclusion and 8, 16, 24, 48, 72, 96, 120, 148, 168 hours following. Measured data points are selected by screening. All measurements are carried out in one lot. ]The investigators follow the severity of oxidative stress in both groups.
- Intensive Care Unit length of stay [ Time Frame: Length of intensive care for each patient (days), data is registered through ICU discharge of the patient, an average of 1 month. ]The investigators assessed the duration of ICU stay (in days)
- Volume resuscitation fluid need of our patients. [ Time Frame: Results are summarised daily for our patients during the first week following inclusion. ]The investigators assess the primary volume resuscitation need of our patients.
- Vasopressor need of our patients. [ Time Frame: Results are summarised daily for our patients during the first week following inclusion. ]The investigators assess the daily average vasopressor dose of our patients.
- Length of mechanical ventilation (if needed). [ Time Frame: Length of mechanical ventillation (days). Data is registered through patient discharge from ICU, an average of 1 month. ]The investigators assess whether CytoSorb treatment reduce the length of mechanical ventilation
- Severity of organ failures according to SOFA point system [ Time Frame: Assessed daily for each patient during the first week of our study. Worst results are registered. ]The investigators assess the severity of multiple organ dysfunction/failure according to SOFA score.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- informed consent of our patient or next of kin,
- TBSA >20% with 2/b depth of burn
Exclusion Criteria:
- non-thermal burn injury,
- need for acute haemodialysis (intoxication),
- immunosuppressive treatment, chronic steroid use (> 3 months),
- known malignant disease,
- end-stage renal insufficiency or renal transplantation,
- Child C hepatic cirrhosis,
- gravidity,
- potentially lethal burn (Baux index >120) or comorbidities

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04195126
Contact: Gábor Woth, MD PhD | +36703729231 | glwoth@gmail.com | |
Contact: Tamás Kiss, MD PhD | kisstamasmd@gmail.com |
Hungary | |
University of Pécs, Dept. of Anaesthesia and Intensive Care | |
Pécs, Baranya County, Hungary, 7622 | |
Contact: Gábor Woth, MD PhD +36703729231 woth.gabor@pte.hu | |
Contact: Tamás Kiss, MD PHD kiss.tamas@pte.hu | |
Principal Investigator: Gábor Woth, MD PhD | |
Sub-Investigator: Bálint Nagy, MD PhD | |
Sub-Investigator: Tamás Kiss, MD PhD | |
Sub-Investigator: Zsófia Kriszta, MD | |
Sub-Investigator: Krisztina Kovács, MD PHD | |
Sub-Investigator: Lajos Bogár, MD PhD Prof | |
Sub-Investigator: Diana Mühl, MD PHD Prof | |
Sub-Investigator: Csaba Csontos, MD PHD |
Principal Investigator: | Gábor Woth, MD PhD | University of Pécs, Dept. of Anaesthesia and Intensive Care |
Responsible Party: | University of Pecs |
ClinicalTrials.gov Identifier: | NCT04195126 |
Other Study ID Numbers: |
7066 - PTE 2018 |
First Posted: | December 11, 2019 Key Record Dates |
Last Update Posted: | December 11, 2019 |
Last Verified: | December 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | The investigators plan to share patient clinical data and laboratory measurement results following study result publication. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Renal Insufficiency Multiple Organ Failure Burns Wounds and Injuries |
Kidney Diseases Urologic Diseases Shock Pathologic Processes |